|
Quality assessment of the included studies |
||||
| Liu [22] |
Page [24] |
Page [25] |
Page [23] |
|
|
|
||||
| Selection of prognostic homogenous study population (disease progression) |
1 |
3 |
3 |
3 |
| Concealment of random allocation |
1 |
3 |
3 |
3 |
| Prestratification of prognostically relevant variables |
3 |
3 |
3 |
3 |
| Random allocation (description of procedure) |
2 |
1 |
1 |
3 |
| Registration of loss to follow-up |
1 |
3 |
4 |
4 |
| Blinding of patients |
4 |
4 |
4 |
4 |
| Blinding of persons who implement interventions |
4 |
4 |
4 |
4 |
| Registration of co-interventions that bear on outcome for each group |
3 |
3 |
1 |
3 |
| Blinding of persons who assess treatment effects |
3 |
1 |
1 |
3 |
| Check to what extent blinding was successful |
3 |
3 |
3 |
3 |
|
1 = Item is properly addressed, 2 = Item is partially addressed, 3 = Item is not properly addressed or not stated, 4 = Item is not applicable | ||||
Zimmermann-Schlatter et al. Journal of NeuroEngineering and Rehabilitation 2008 5:8 doi:10.1186/1743-0003-5-8 |
||||